S
Sharon Yim
Researcher at Medical College of Wisconsin
Publications - 6
Citations - 301
Sharon Yim is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Internal medicine & Chimeric antigen receptor. The author has an hindex of 3, co-authored 3 publications receiving 123 citations.
Papers
More filters
Journal ArticleDOI
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah,Bryon D. Johnson,Dina Schneider,Fenlu Zhu,Aniko Szabo,Carolyn A. Keever-Taylor,Winfried Krueger,Andrew Worden,Michael Kadan,Sharon Yim,Ashley M. Cunningham,Mehdi Hamadani,Timothy S. Fenske,Boro Dropulic,Rimas J. Orentas,Rimas J. Orentas,Parameswaran Hari +16 more
TL;DR: On-site manufacturing and infusion of non-cryopreserved LV20.19 CAR T cells were feasible and therapeutically safe, showing low toxicity and high efficacy, and loss of the CD19 antigen was not seen in patients who relapsed or experienced treatment failure.
Journal ArticleDOI
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease.
William R. Drobyski,Aniko Szabo,Fenlu Zhu,Carolyn A. Keever-Taylor,Kyle Hebert,Renee Dunn,Sharon Yim,Bryon D. Johnson,Anita D'Souza,Mary Eapen,Timothy S. Fenske,Parameswaran Hari,Mehdi Hamadani,Mary M. Horowitz,J. Douglas Rizzo,Wael Saber,Nirav N. Shah,Bronwen E. Shaw,Marcelo C. Pasquini +18 more
TL;DR: It is concluded that tocilizumab has promising activity in preventing acute graft-versus-host disease, particularly in the lower gastrointestinal tract, and warrants examination in a randomized setting.
Journal ArticleDOI
A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma
Nirav N. Shah,Fenlu Zhu,Carolyn Taylor,Dina Schneider,Winfried Krueger,Andrew Worden,Sharon Yim,Timothy S. Fenske,Mehdi Hamadani,Bryon D. Johnson,Boro Dropulic,Rimas Orentas,Parameswaran Hari +12 more
TL;DR: A Phase 1 clinical trial evaluating a first-in-human bispecific tandem CAR-T cell directed against both CD19 and CD20 (CAR-20) antigens for patients with R/R B-cell NHL to demonstrate feasibility and safety and eliminate third party shipping logistics.
Journal ArticleDOI
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
J. M. Knight,A. Szabó,Igli Arapi,Ruizhe Wu,Amanda Emmrich,Edward Hackett,Garrett Sauber,Sharon Yim,Bryon D. Johnson,Parameswaran Hari,Dina Schneider,Boro Dropulic,Rachel Cusatis,Steve W. Cole,Cecilia J. Hillard,Nirav N. Shah +15 more
TL;DR: In this paper , the authors examined the impact of CAR T cell therapy on blood markers associated with depression, anxiety, pain, fatigue, and poor sleep, and found that the amount of kynurenine, a normal blood constituent, and related molecules was higher in patients who experienced significant CART cell side effects on the brain and in patients reporting more depression.
Journal ArticleDOI
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.
J. M. Knight,Aniko Szabo,Igli Arapi,Ruizhe Wu,Amanda Emmrich,Edward Hackett,Garrett Sauber,Sharon Yim,Bryon D. Johnson,Parameswaran Hari,Dina Schneider,Boro Dropulic,Rachel Cusatis,Steve W. Cole,Cecilia J. Hillard,Nirav N. Shah +15 more
TL;DR: In this paper , the authors examined the impact of CAR T cell therapy on blood markers associated with depression, anxiety, pain, fatigue, and poor sleep, and found that the amount of kynurenine, a normal blood constituent, and related molecules was higher in patients who experienced significant CART cell side effects on the brain and in patients reporting more depression.